Which disease-relevant molecular pathways and gene-network modules most plausibly drive ALS/FTD initiation and progression, and what causal experiments (e.g., perturbation, single-cell/spatial profili

The pathogenesis of Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD) is driven by a convergent clinicopathological spectrum involving aberrant RNA metabolism, proteostasis collapse, and neuroinflammatory remodeling (Direct; PMID: 27830784, 25652699). Causal mechanisms prioritize the interaction between misfolded protein species (e.g., TDP-43, SOD1) and non-cell-autonomous glial networks that exacerbate neuronal vulnerability (Direct; PMID: 37296571, 41596533).

Core Molecular Pathways in ALS/FTD

• RNA Metabolism and Splicing Dysregulation: Nuclear depletion and cytoplasmic aggregation of TDP-43 occur in 97% of ALS and 50% of FTD cases, leading to loss of critical splicing regulation (e.g., STMN2, UNC13A) and gain of cytoplasmic toxicity (Direct; PMID: 25652699, 41677614). Mutations in FUS, MATR3, and hnRNPA1 further emphasize RNA processing as a primary driver (Direct; PMID: 27830784, 41621017).
• Proteostasis and Autophagy Failure: Mutations in VCP, SQSTM1, UBQLN2, and OPTN impair the clearance of misfolded proteins through the ubiquitin-proteasome system (UPS) and autophagy, favoring the formation of neurotoxic aggresomes (Direct; PMID: 25652699, 41562832).
• C9orf72 Hexanucleotide Repeat Expansion: The GGGGCC expansion in C9orf72—the most common genetic cause—drives pathology via three non-exclusive mechanisms: haploinsufficiency, toxic RNA foci sequestering RNA-binding proteins, and repeat-associated non-AUG (RAN) translation of dipeptide repeat proteins (DPRs) (Direct; PMID: 21944778, 27830784).
• Mitochondrial and Metabolic Dysfunction: Mutant SOD1 and TDP-43 aggregates invade mitochondria, triggering mtDNA release and activating the cGAS-STING inflammatory pathway (Direct; PMID: 37433768, 41562832). In astrocytes, deficiency in the glycogen phosphorylase PYGM disrupts lactate-mediated metabolic support, exacerbating neuronal tau phosphorylation (Direct; PMID: 41700129).
• Axonal and Cytoskeletal Dynamics: Mutations in KIF5A, DYNC1H1, and DCTN1 disrupt anterograde and retrograde transport, contributing to the "dying-back" degeneration of upper and lower motor neurons (Direct; PMID: 41621017, 41646374).

Pathological Gene-Network Modules

• A1-like Neurotoxic Astrocytes: Induced by microglial-derived cytokines (TNF-α, IL-1α, C1q), this module involves the upregulation of the classical complement cascade (e.g., C3). A1 astrocytes lose the ability to promote synaptogenesis and instead secrete unidentified toxins that kill neurons and oligodendrocytes (Direct; PMID: 28099414, 33589835).
• Disease-Associated Microglia (DAM): Characterized by the downregulation of homeostatic markers (e.g., P2RY12) and upregulation of inflammatory/phagocytic genes (e.g., TREM2, APOE, SPP1), this module regulates the clearance of pathological aggregates but may also facilitate synapse loss (Direct; PMID: 28602351, 37735487).
• Microglial Switch (M2 to M1): In ALS models, microglia initially adopt a protective M2 phenotype but transition to a neurotoxic M1 phenotype during rapid disease progression, characterized by high NOX2 and pro-inflammatory cytokine expression (Direct; PMID: 41596533, 41639687).

Prioritized Causal Experiments for Validation

• Isogenic CRISPR/Cas9 Perturbation: Prioritize using CRISPR/Cas9 to correct or introduce specific mutations (e.g., C9orf72, TARDBP) in human iPSCs to isolate cell-autonomous versus non-cell-autonomous effects in defined motor neuron and glial populations (Direct; PMID: 41677614, 41569436).
• 3D Microphysiological Systems (Organ-on-Chip): Utilize "ALS-on-a-chip" motor units or neuromuscular junction (NMJ) organoids containing motor neurons, skeletal muscle, and Schwann cells. These platforms permit longitudinal, quantitative functional readouts (e.g., muscle contraction) after specific molecular perturbations (Direct; PMID: 41677614).
• Spatial Transcriptomics and snRNA-seq: Map microglial and astrocytic heterogeneity across brain regions (e.g., motor cortex vs. cerebellum) to determine why certain circuits are selectively vulnerable despite ubiquitous gene expression (Direct; PMID: 37296571, 41683913).
• Glial Depletion and Replacement: Validate glial contributions by pharmacologically depleting microglia (e.g., CSF1R inhibitors) or transplanting wild-type glial precursors into mutant mouse models to assess rescue of motor function (Direct; PMID: 37296571, 28099414).
• Multi-omics Integration (RNA/Proteome/Lipidome): Combine single-cell transcriptomics with extracellular vesicle (EV) proteomics to track phase-specific biomarkers (e.g., STMN2 splicing fragments) that correlate with in vivo disease progression (Direct; PMID: 41516374, 41599177).

Synthesis

ALS and FTD are essentially "network diseases" where the collapse of RNA processing and proteostasis in motor neurons is amplified by neurotoxic gene modules in glia (Derived; PMID: 25652699, 28099414, 41562832). While association studies have identified dozens of risk genes, causal validation must focus on the temporal "switch" from homeostatic to neurotoxic states (Derived; PMID: 33589835, 41639687). The most promising mechanistic hub for intervention is the normalization of the TDP-43-dependent splicing network and the restoration of glial metabolic support (e.g., lactate shuttling) (Derived; PMID: 41677614, 41700129).

Evidence Quality: Strong for genetic causation and pathological markers (TDP-43, C9orf72); Moderate for specific glial subtype functions in human disease; Weak for direct causal links of gut-brain axis interactions in humans.

Limitations: Most mechanistic data rely on SOD1 or TDP-43 overexpression rodent models, which may not fully recapitulate the biology of sporadic ALS/FTD (PMID: 37296571, 41599368). Human post-mortem data provide only end-stage snapshots, requiring greater reliance on emerging longitudinal iPSC and imaging technologies (PMID: 41516374, 41677614).